美企申請向中芯(00981.HK)交貨未獲華府批准
據《路透》引述消息指,全球晶片供應短缺情況持續,而美國政府在審批美企出口晶片生產設備予中芯國際(00981.HK)的進展仍然緩慢,消息人士指很多美國設備及原材料供應商的出口許可均未獲批,貨值達50億美元,部分企業在中芯於去年12月被列入黑名單後便迅速遞交許可申請,不過僅部分出口許可獲批,當中包括少數昂貴的設備。
報道指正常出口許可申請應在一個月內獲批,不過官員就申請向企業追問,以判斷零件或零部件會否被用於生產10nm或以下的晶片,以致申請時間被延長。(el/k) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.